Clinical trial · Interventional
Suzetrigine vs Norco-postoperative Mohs Pain
Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone/Acetaminophen
NCT07575230CI-TRIAL-00110993enrolling by invitationPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous Tumors | Skin Neoplasm | PROBABILISTIC | 0.70 |
| Mohs Micrographic Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Norco 5Mg-325Mg Tablet | Drug | — | UNRESOLVED |
| Suzetrigine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard of Care
- description
- Participants will receive the standard of care drug Norco (a medicine that combines hydrocodone and acetaminophen).
- interventionNames
- Drug: Norco 5Mg-325Mg Tablet
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Participants will receive the control drug, Suzetrigine.
- interventionNames
- Drug: Suzetrigine
Primary outcomes (1)
- measure
- Change in need for opioid medication for pain management after Mohs micrographic surgery
- timeFrame
- 48hours post surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * adults between the age of 18-89 * individuals who have a cutaneous tumor treated by MMS Exclusion Criteria: * individuals younger than 18 and older than 89 * individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway * individuals with liver disease
References
Publications (2)
- BACKGROUNDAd Hoc Task Force; Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, Zalla MJ, Brewer JD, Smith Begolka W; Ratings Panel; Berger TG, Bigby M, Bolognia JL, Brodland DG, Collins S, Cronin TA Jr, Dahl MV, Grant-Kels JM, Hanke CW, Hruza GJ, James WD, Lober CW, McBurney EI, Norton SA, Roenigk RK, Wheeland RG, Wisco OJ. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012 Oct;67(4):531-50. doi: 10.1016/j.jaad.2012.06.009. Epub 2012 Sep 5. PMID 22959232
- BACKGROUNDPhillips, Shay, et al.